GENTICEL (Euronext Paris and Brussels: FR0011790542 – GTCL), a French biotechnology company and leading developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), updates its financial calendar for 2016 and announces schedule of participation in key conferences during the first half of 2016.
FINANCIAL CALENDAR 2016 (UPDATED)
|March 14||2015 Annual Results
(before Euronext market opening)
|April 28||Business & Cash Position Update 1st Quarter 2016|
|June 9||Annual General Meeting in Paris|
|July 28||Business & Cash Position Update 2nd Quarter 2016|
|September 22||2016 Half-Year Results|
|October 27||Business & Cash Position Update 3rd Quarter 2016|
This financial calendar is for indicative purposes only and Genticel could change its publication dates if deemed necessary.
INVESTOR RELATIONS CONFERENCES
|March 14||Paris||sfaf meeting on 2015 annual results and 2016 outlook
(French Society of Financial Analysts)
|March 22||Brussels||KBC Securities Healthcare Conference|
|April 11-12||Paris||Small & Midcap Event|
|April 16||Antwerp||VFB Happening 2016 (Flemish Federation of Investors)|
|June 29-30||Paris||Spring Midcap Event|
BUSINESS DEVELOPMENT & SCIENTIFIC CONFERENCES
|March 21-23||Washington, DC||Targeted Anticancer Therapies (TAT) 2016 Congress|
|April 4-6||Stockholm||Bio-Europe Spring 2016|
|June 3-7||Chicago, IL||American Society Of Clinical Oncology (ASCO) 2016 Annual meeting|
|June 6-9||San Francisco||2016 BIO International Convention|
|June 15-18||Salzburg||EUROGIN 2016|
This conference calendar is for information purposes only.
Aiming to solve a public health issue.
Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. The company has already completed patient recruitment for the phase 2 clinical trial of GTL001 in Europe.
Offering a promising technological platform.
Genticel's versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel's second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.
Focusing on value creation.
Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addtion to this attractive HPV product pipeline, Genticel's versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world's largest producer of vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.
For more information, visit us at www.genticel.com
This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015 and those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only and are not otherwise available for distribution or sale.
Investor Relations & Corporate Communications
+ 33 6 33 34 37 30
|US – Life Sci Advisors
+1 212 915 2578
+33 1 53 67 36 77
Caroline Carmagnol et
+33 6 64 18 99 59 / +33 6 47 38 90 04